Bristol Myers Squibb Says EMA Validated Its Type II Variation Application For Opdivo Plus Yervoy For First-Line Treatment Of Unresectable Or Advanced Hepatocellular Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II Variation Application for the combination of Opdivo and Yervoy as a first-line treatment for unresectable or advanced hepatocellular carcinoma.
July 19, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's Type II Variation Application for Opdivo and Yervoy has been validated by the EMA, potentially expanding the use of these drugs for advanced hepatocellular carcinoma.
The validation by the EMA is a significant regulatory milestone that could lead to expanded use of Opdivo and Yervoy, potentially increasing revenue for Bristol Myers Squibb.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100